Riskpilot← Back to searchSign inGet full accessScandiCure AB
ABActiveOrg 5590721428Jakobshöjdsvägen 8Leasing of intellectual property and similar products, except copyrighted works · NACE 7740Est. 20160 employees
Revenue 2025
SEK 0
EBITDA margin
—
-309% vs 2024
Equity ratio
99.2%
Financial strength
Net profit 2025
SEK -12K
-947% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -15K | -309% |
| Net profit | SEK -12K | -947% |
| Total assets | SEK 42K | -23% |
| Equity | SEK 41K | -23% |
| Employees | 0 | — |
Legal name
ScandiCure AB
Org number
5590721428
Legal form
Aktiebolag
NACE code
7740 · Leasing of intellectual property and similar products, except copyrighted works
Founded
8 augusti 2016
Share capital
SEK 51 600
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-11-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Mahlapuu, Margit
Company purpose
Äga och förvalta uppfinningar relaterade till sjukdomar och deras behandling och därtill jämförbar verksamhet samt förvalta fast egendom och värdepapper.
Address
Jakobshöjdsvägen 8
Email
n.falkmer@scanjet.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −25 | −11 | −20 | −4 | −15 |
| Depreciation & amort. | −0 | −0 | −0 | — | — |
| EBIT | −25 | −11 | −20 | −4 | −15 |
| Net financials | — | — | — | 5 | 2 |
| Profit before tax | −2 | −2 | 200 | 2 | −12 |
| Tax | −0 | −0 | −45 | −0 | — |
| Net profit | −2 | −2 | 155 | 1 | −12 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 436 | 426 | 416 | 54 | 42 |
| Equity | 209 | 207 | 362 | 54 | 41 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 0 | 0 | 55 | 0 | 0 |
| Total debt | — | — | 55 | 0 | 0 |
EBITDA margin
-1450200.0%
This company
15.8%
Market median
-9178581% vs market
20212025
Equity ratio
99.2%
This company
38.2%
Market median
+160% vs market
20212025
Return on equity
-30.1%
This company
18.4%
Market median
-264% vs market
20212025
Net profit margin
-1241900.0%
This company
8.1%
Market median
-15332199% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-12-01 – 2025-11-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-12-01 – 2024-11-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-12-01 – 2023-11-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-12-01 – 2022-11-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-12-01 – 2021-11-30
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2022 | |
| Chairman | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ScandiCure AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lorna May Fletcher | Board of Directors | 0 companies |
| Per Jesper Dahlberg | Deputy Board Member | 0 companies |
| Lars Niklas Falkmer | Deputy Board Member | 0 companies |
| Margit Mahlapuu | Chairman | 0 companies |